Review: Cardiovascular toxicities due to molecularly targeted cancer therapeutics

Clinical Advances in Hematology and Oncology

Volumn 8, Issue 2, 2010, Pages 133-135

  Chintalgattu, Vishnu ^a   Khakoo, Aarif Y ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 5 (4 BROMO 2 CHLOROANILINO) 4 FLUORO 1 METHYL 1H BENZIMIDAZOLE 6 CARBOHYDROXAMIC ACID 2 HYDROXYETHYL ESTER; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CP 751871; DASATINIB; DEPSIPEPTIDE; GSK 6909693; GSK 909693; IMATINIB; IMCA 12; LAPATINIB; MITOXANTRONE; N (2 AMINOPHENYL) 4 [4 (3 PYRIDINYL) 2 PYRIMIDINYLAMINOMETHYL]BENZAMIDE; NILOTINIB; PERIFOSINE; RDEA 119; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG; VORINOSTAT; XL 765;

ACUTE LYMPHOBLASTIC LEUKEMIA; BREAST CANCER; CARDIOMYOPATHY; CARDIOTOXICITY; CENTRAL NERVOUS SYSTEM TUMOR; CHRONIC MYELOID LEUKEMIA; CONGESTIVE CARDIOMYOPATHY; DRUG SAFETY; DRUG TARGETING; ENDOPLASMIC RETICULUM STRESS; GASTROINTESTINAL STROMAL TUMOR; HEAD AND NECK CANCER; HEART FAILURE; HEART HYPERTROPHY; HIGH RISK PATIENT; HUMAN; HYPERTENSION; LEUKEMIA; LUNG CANCER; LYMPHOMA; MELANOMA; METASTASIS; MONOTHERAPY; MYELOMA; NONHUMAN; NOTE; OVARY CANCER; SARCOMA;

CARDIOMYOPATHY, DILATED; CARDIOMYOPATHY, HYPERTROPHIC; CARDIOTOXINS; HEART FAILURE; HUMANS; NEOPLASMS; PROTEIN KINASE INHIBITORS;

EID: 77749273490     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (13)

1. Khakoo AY, Yeh ET. Therapy insight: management of cardiovascular disease in patients with cancer and cardiac complications of cancer therapy. Nat Clin Pract Oncol. 2008;5:655-667.
2. Gianni L, Herman EH, Lipshultz SE, Minotti G, Sarvazyan N, Sawyer DB. Anthracycline cardiotoxicity: from bench to bedside. J Clin Oncol. 2008;26:3777-3784.
3. Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl J Med. 2005;353:172-187.
4. Francis J, Ahluwalia MS, Wetzler M, et al. Reversible cardiotoxicity with tyrosine kinase inhibitors. Clin Adv Hematol Oncol. 2010;8:128-132.
5. Kerkelä R, Grazette L, Yacobi R, et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med. 2006;12:908-916.
6. Trent JC, Patel SS, Zhang J, et al. Rare incidence of congestive heart failure in gastrointestinal stromal tumor and other sarcoma patients receiving imatinib mesylate (IM) therapy. Cancer. 2010;116:184-192.
7. Atallah E, Durand JB, Kantarjian H, Cortes J. Congestive heart failure is a rare event in patients receiving imatinib therapy. Blood. 2007;110:1233-1237.
8. Ribera JM, Oriol A, Gonzalez M, et al. Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial. Haematologica. 2010;95:87-95.
9. Ewer MS, Lippman SM. Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol. 2005;23:2900-2902.
10. Chu TF, Rupnick MA, Kerkela R, et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet. 2007;370:2011-2019.
11. Bhargava P. VEGF kinase inhibitors: how do they cause hypertension? Am J Physiol Regul Integr Comp Physiol. 2009;297:R1-R5.
12. Khakoo AY, Kassiotis CM, Tannir N, et al. Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor. Cancer. 2008;112:2500-2508.
13. Schmidinger M, Zielinski CC, Vogl UM, et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2008;26:5204-5212.